3-Methyl-6-t-butyl-s-tetrazin | 34753-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四嗪
• 英文名称: 3-Methyl-6-t-butyl-s-tetrazin
• 英文别名: 3-tert-butyl-6-methyl-[1,2,4,5]tetrazine；3-Tert-butyl-6-methyl-1,2,4,5-tetrazine
• CAS: 34753-05-4
• 化学式: C₇H₁₂N₄
• 分子量: 152.199
• InChiKey: UHLZCGMYRRQTRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Sustained release delivery systems comprising traceless linkers
  申请人：NOVARTIS AG

  公开号：US10751417B2

  公开（公告）日：2020-08-25

  Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

  本文描述了用于递送生物活性制剂的药物递送系统，该系统包含伯胺或仲胺或杂杂芳环的环氮原子、其药学上可接受的盐、与之相关的药物递送试剂、包含该药物递送系统的药物组合物，以及该药物递送系统作为缓释治疗剂的用途。
• ANDROGEN RECEPTOR ANTAGONISTS
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20170101384A1

  公开（公告）日：2017-04-13

  Disclosed herein are compositions and methods for modulating the androgen receptor.
• SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS
  申请人：Novartis AG

  公开号：US20200376129A1

  公开（公告）日：2020-12-03

  Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.
• SUSTAINED DELIVERY OF ANGIOPOETIN-LIKE 3 POLYPEPTIDES
  申请人：Novartis AG

  公开号：US20220323595A1

  公开（公告）日：2022-10-13

  Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.